Yael Cohen, MD | Authors

Yael Cohen, MD, on MRD Negativity Following Treatment With Cilta-Cel in Refractory Myeloma

January 24, 2022

In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.